BliNK Biomedical
Lyon
About BliNK Biomedical
BliNK Biomedical SAS specializes in the discovery and development of first or best-in-class antibody-based therapeutics for life threatening diseases such as cancer with a focus on immuno-oncology disease targets. Our lead program is a monoclonal antibody that targets an immune checkpoint to cause an immune switch that renders tumors susceptible to the body's immune system. Our other programs address a number of attractive, novel immuno-oncology and immune-checkpoint targets, some of which are unique to our approach. The antibodies that we are developing have the potential to be the next generation of anti-tumor therapeutics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2016)
- Website: blinkbiomedical.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/blink-biomedical-197312 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.